Sugi Predict

Sugi Predict / Compounds / SCHEMBL57185

SCHEMBL57185

SCHEMBL57185

[c]1nc(-c2ccccc2)n[c]c1-c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 5/20 0.48
▸ NPC1 O15118 4/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ NFKB1 P19838 2/20 0.41
▸ NFKB2 Q00653 2/20 0.41
▸ RELA Q04206 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ ADORA2A P29274 4/20 0.39
▸ ADORA1 P30542 4/20 0.39
▸ ADORA3 P0DMS8 3/20 0.39
▸ ADORA2B P29275 3/20 0.39
▸ POLB P06746 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ NR1H4 Q96RI1 1/20 0.37
▸ MEN1 O00255 4/20 0.35
▸ KMT2A Q03164 4/20 0.35
▸ NR1H2 P55055 2/20 0.35
▸ NR1H3 Q13133 2/20 0.35
▸ HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9322432 0.72 RAB9A (0.50) RAB9ANPC1MAPK1NFKB1NFKB2
SCHEMBL70355 0.67 NPC1 (0.44) RAB9ANPC1MAPK1NFKB1NFKB2
SCHEMBL1870772 0.67 L3MBTL1 (0.52) RAB9ANPC1MAPK1NFKB1NFKB2
SCHEMBL3652642 0.66 NPC1 (1.00) RAB9ANPC1MAPK1NFKB1NFKB2
SCHEMBL371042 0.66 L3MBTL1 (0.74) RAB9ANPC1MAPK1NFKB1NFKB2
SCHEMBL18212420 0.64 L3MBTL1 (0.70) RAB9ANPC1MAPK1NFKB1NFKB2
SCHEMBL17720978 0.64 L3MBTL1 (0.70) RAB9ANPC1MAPK1NFKB1NFKB2
SCHEMBL75848 0.64 L3MBTL1 (0.70) RAB9ANPC1MAPK1NFKB1NFKB2
SCHEMBL6112014 0.64 L3MBTL1 (0.70) RAB9ANPC1MAPK1NFKB1NFKB2
SCHEMBL6366584 0.63 RAB9A (0.68) RAB9ANPC1MAPK1NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11883420-B2 Sting agonists for treating bladder cancer and solid tumors Venenum Biodesign, LLC (US) 2024-01-30 — — US disclosed
WO-2023239906-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-12-14 — — WO disclosed
EP-3873484-B1 NOVEL STING AGONISTS VENENUM BIODESIGN LLC (US) 2023-08-23 — — EP disclosed
CN-108884044-B Piperidine derivatives 大塚制药株式会社 2023-01-31 — — CN disclosed
US-20220048936-A1 NOVEL STING AGONISTS Venenum Biodesign, LLC (US) 2022-02-17 — — US disclosed
US-11161864-B2 Sting agonists Venenum Biodesign, LLC (US) 2021-11-02 — — US disclosed
US-20210290645-A1 STING AGONISTS FOR TREATING BLADDER CANCER AND SOLID TUMORS Venenum Biodesign, LLC (US) 2021-09-23 — — US disclosed
EP-3873484-A1 NOVEL STING AGONISTS Venenum Biodesign, LLC (US) 2021-09-08 — — EP disclosed
US-11110106-B2 Sting agonists for treating bladder cancer and solid tumors Venenum Biodesign, LLC (US) 2021-09-07 — — US disclosed
US-20210060041-A1 STING AGONISTS FOR TREATING BLADDER CANCER AND SOLID TUMORS Venenum Biodesign, LLC (US) 2021-03-04 — — US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 — — US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 — — EP disclosed
EP-2181105-A1 N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL)-3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS Novartis Ag (CH) 2010-05-05 — — EP disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 — — US disclosed
WO-2009000811-A1 N5-(2-ETHOXYETHYL)-N3-(2-PYRIDINYL)-3,5-PIPERIDINEDICARBOXAMIDE DERIVATIVES FOR USE AS RENIN INHIBITORS NOVARTIS AG (CH) 2008-12-31 — — WO disclosed
US-20080319018-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2008-12-25 — — US disclosed
EP-1968940-A1 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS Novartis AG (CH) 2008-09-17 — — EP disclosed
US-20080058533-A1 PYRANOINDAZOLE CYCLIC CARBONATES AND METHODS OF USE ALCON, INC. (US) 2008-03-06 — — US disclosed
WO-2008028021-A2 PYRANOINDAZOLE CYCLIC CARBONATES AND THEIR USE ALCON, INC. (CH) 2008-03-06 — — WO disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210290645-A1 STING AGONISTS FOR TREATING BLADDER CANCER AND SOLID TUMORS STING1, CGAS, TBK1 RAB9A 884/4885NPC1 2985/4885MAPK1 2919/4885
US-11161864-B2 Sting agonists STING1, IRF3, CGAS RAB9A 1577/4885NPC1 1468/4885MAPK1 2147/4885
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 RAB9A 500/4885NPC1 2676/4885MAPK1 3191/4885
US-20080319018-A1 ORGANIC COMPOUNDS REN, ACE, AGTR1 RAB9A 968/4885NPC1 2490/4885MAPK1 3365/4885
US-11883420-B2 Sting agonists for treating bladder cancer and solid tumors STING1, CGAS, TBK1 RAB9A 884/4885NPC1 2985/4885MAPK1 2919/4885
US-20210060041-A1 STING AGONISTS FOR TREATING BLADDER CANCER AND SOLID TUMORS STING1, CGAS, TBK1 RAB9A 884/4885NPC1 2985/4885MAPK1 2919/4885
US-20080058533-A1 PYRANOINDAZOLE CYCLIC CARBONATES AND METHODS OF USE CA3, CYP11B2, PDXK RAB9A 3538/4885NPC1 4229/4885MAPK1 3068/4885
US-11110106-B2 Sting agonists for treating bladder cancer and solid tumors STING1, CGAS, TBK1 RAB9A 884/4885NPC1 2985/4885MAPK1 2919/4885
US-20220048936-A1 NOVEL STING AGONISTS STING1, IRF3, CGAS RAB9A 1381/4885NPC1 1354/4885MAPK1 1805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.